Brokerages expect Teligent Inc (NASDAQ:TLGT) to post $17.73 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Teligent’s earnings, with the highest sales estimate coming in at $17.80 million and the lowest estimate coming in at $17.65 million. Teligent posted sales of $16.10 million during the same quarter last year, which suggests a positive year-over-year growth rate of 10.1%. The company is scheduled to announce its next earnings report on Thursday, March 21st.

According to Zacks, analysts expect that Teligent will report full year sales of $67.32 million for the current financial year, with estimates ranging from $67.24 million to $67.40 million. For the next financial year, analysts expect that the business will report sales of $85.10 million, with estimates ranging from $84.80 million to $85.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Teligent.

Teligent (NASDAQ:TLGT) last released its earnings results on Tuesday, November 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). The firm had revenue of $18.29 million for the quarter, compared to analyst estimates of $19.80 million. Teligent had a negative return on equity of 44.64% and a negative net margin of 54.17%.

A number of research analysts recently issued reports on TLGT shares. ValuEngine raised Teligent from a “hold” rating to a “buy” rating in a report on Friday, November 2nd. Canaccord Genuity lowered their target price on Teligent from $4.00 to $3.00 and set a “hold” rating on the stock in a report on Friday, November 16th.

NASDAQ:TLGT traded up $0.21 during mid-day trading on Friday, reaching $1.74. 895,200 shares of the stock were exchanged, compared to its average volume of 374,525. The firm has a market cap of $77.97 million, a P/E ratio of -9.16 and a beta of 1.39. Teligent has a 1-year low of $1.13 and a 1-year high of $4.52. The company has a quick ratio of 0.86, a current ratio of 1.31 and a debt-to-equity ratio of 3.30.

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc increased its stake in Teligent by 0.7% in the 3rd quarter. Vanguard Group Inc now owns 2,249,427 shares of the company’s stock worth $8,885,000 after purchasing an additional 15,800 shares in the last quarter. BlackRock Inc. increased its stake in Teligent by 0.5% in the 3rd quarter. BlackRock Inc. now owns 3,463,605 shares of the company’s stock worth $13,681,000 after purchasing an additional 16,198 shares in the last quarter. Wells Fargo & Company MN increased its stake in Teligent by 15.9% in the 3rd quarter. Wells Fargo & Company MN now owns 123,329 shares of the company’s stock worth $488,000 after purchasing an additional 16,919 shares in the last quarter. Virtu Financial LLC purchased a new position in Teligent in the 3rd quarter worth about $172,000. Finally, First Light Asset Management LLC increased its stake in Teligent by 4.6% in the 2nd quarter. First Light Asset Management LLC now owns 1,151,032 shares of the company’s stock worth $3,983,000 after purchasing an additional 50,209 shares in the last quarter. 67.75% of the stock is currently owned by hedge funds and other institutional investors.

About Teligent

Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.

Recommended Story: What are the benefits of a balanced fund?

Get a free copy of the Zacks research report on Teligent (TLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.